TR(ACE) Assay Clinical Specimen Study

Inclusion Criteria: * Non-small cell lung: Male or Female Adult patient \>= 21 years old * Breast only: Female Adult patient \>= 21 years old * Previously diagnosed with one of the following cancers: Breast or Non-small Cell Lung * Cancer has progressed to at least Stage III or higher for lung cancer or, * Cancer has progressed to stage IV (metastatic) breast cancer * Participating in standard of care cancer therapy requiring frequent treatments, typically intravenous chemotherapy visits (or as determined by the standard of care for the particular cancer assessed), of a minimum of three (3) treatment visits planned in 9 months from date of enrollment where a clinical assessment will be conducted Exclusion Criteria: * Physician assessment that obtaining two extra whole blood specimens with minimum volume of 5 mL per treatment visit is contraindicated * Stage I and II Non-small Cell Lung Cancer * Stage I through III breast cancer * Pregnant or planning to become pregnant during the course of the study * Unable to obtain informed consent from subject or their legal representative * Life expectancy is less than 9 months * Presence of one or more of the following other chronic diseases * Another type of cancer except for non-melanomatous skin tumors * Autoimmune disease requiring DMARDS or Biologics * Infectious disease requiring prolonged intravenous antibiotics or hospitalization * Renal disease specifically those in End Stage Renal Failure * Recent (\< 3 weeks) major trauma or major surgical procedure(s) or radiation therapy prior to enrollment in the study * Recent (\< 2 months) major occlusive arterial event such as MI or CVA prior to enrollment in the study